[1]胡佳丽,兰春慧,张昊翔,等.不同疗程铋剂四联疗法在中国根治幽门螺杆菌感染疗效的Meta分析[J].第三军医大学学报,2017,39(10):1044-1055.
 Hu Jiali,Lan Chunhui,Zhang Haoxiang,et al.Efficacy of different durations of bismuth-based quadruple therapy for Helicobacter pylori infection in China: a meta-analysis[J].J Third Mil Med Univ,2017,39(10):1044-1055.
点击复制

不同疗程铋剂四联疗法在中国根治幽门螺杆菌感染疗效的Meta分析(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
39卷
期数:
2017年第10期
页码:
1044-1055
栏目:
公共卫生与预防医学
出版日期:
2017-05-30

文章信息/Info

Title:
Efficacy of different durations of bismuth-based quadruple therapy for Helicobacter pylori infection in China: a meta-analysis
作者:
胡佳丽兰春慧张昊翔沈才飞王璞冯吉代剑华闫武夏一菊何金龙陈文生房殿春
第三军医大学西南医院全军消化病研究所;第三军医大学大坪医院野战外科研究所消化内科
Author(s):
Hu Jiali Lan Chunhui Zhang Haoxiang Shen Caifei Wang Pu Feng Ji Dai Jianhua Yan Wu  Xia Yiju He JinlongChen Wensheng Fang Dianchun

Institute of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing, 400038; Department of Gastroenterology, Institute of Surgery Research, Daping hospital, Third Military Medical University, Chongqing, 400042, China

关键词:
幽门螺杆菌铋剂四联疗法三联疗法序贯疗法伴随疗法
Keywords:
Helicobacter pylori bismuth quadruple therapy triple therapy sequential therapy concomitant therapy
分类号:
R516; R573; R975
文献标志码:
A
摘要:

目的       评价不同疗程(10 d或14 d)铋剂四联疗法在中国幽门螺杆菌感染的根除疗效及安全性。方法       计算机检索2005年1月至2016年11月Pubmed、EMBASE、the Cochrane Central Register of Controlled Trials、中国知网、中国生物医学文献数据库、维普等数据库关于10 d或14 d铋剂四联疗法在中国根除幽门螺杆菌感染的随机对照试验,提取受试者的基本资料、观察指标(根除率及不良反应发生率)、研究质量等相关数据,使用RevMan 5.3软件分析相关指标,计算RR及95% CI,使用漏斗图行发表偏倚评价。结果纳入43篇文献,共7 686例患者。合并结果显示:据意向性分析,10 d或14 d铋剂四联疗法和三联疗法根除率分别是88.96%(95% CI:87.73%~90.19%)和74.11%(95% CI:72.53%~75.69%),差异有统计学意义(RR=1.20,95% CI:1.16%~1.25%);10 d或14 d铋剂四联疗法和 7 d 铋剂四联疗法相比,根除率分别是87.34%(95% CI:84.87%~89.80%)、81.65%(95% CI:78.76%~84.54%)(意向性分析),差异有统计学意义(RR=1.07,95% CI:1.02%~1.12%);10 d或14 d铋剂四联联疗法与序贯疗法(RR=1.02,95% CI:0.97%~1.07%)及与伴随疗法(RR=1.01,95% CI:0.95%~1.07%)差异无统计学意义。结论       10 d或14 d铋剂四联疗法与序贯疗法及伴随疗法疗效相当,三联疗法及7 d铋剂四联疗法不作为首选治疗方案

Abstract:

Objective        To assess the efficacy and safety of bismuth quadruple therapy for 10 or 14 days in eradicating Helicobacter pylori(H.pylori) infections in Chinese patients. Methods      The databases including PubMed, Embase, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure Database, Chinese Biomedical Database and VIP database were searched for randomized controlled trials (RCTs) published from the year  2005 to 2016 describing bismuthbased quadruple therapy for 10 or 14 days in Chinese patients. The trails retrieved were examined for clinical features of patients, quality of study, eradication rate of H.pylori and incidence of adverse events. A meta-analysis of the included trials was performed using Revman 5.3 software, and the pooled relative risk (RR) and 95% confidence intervals (CIs) were calculated; the publication bias was assessed with funnel plot. Results       Forty-three trials involving a total of 7 686 patients were eligible for inclusion in the analysis.  Intention-to-treat analysis showed that the eradication rate of H.pylori was 88.96% (95% CI: 87.73%~90.19%) with bismuth quadruple therapy for 10 or 14 d and 74.11% (95% CI: 72.53%~75.69%) with triple therapy, showing a significant difference in the efficacy between the 2 therapies (RR=1.20, 95% CI:1.16%~1.25%). Analysis of 9 trials comparing bismuth quadruple therapy for 10 or 14 d and for 7 d showed that a treatment duration for 10 or 14 d resulted in an significantly higher eradication rate than a treatment duration of 7 days[87.34% (95% CI: 84.87%~89.80%) vs 81.65% (95% CI: 78.76%~84.54%), RR=1.07, 95% CI: 1.02%~1.12%]. The eradication rate produced by bismuth quadruple therapy for 10 or 14 d did not differ significantly from that by sequential therapy (RR=1.02, 95% CI: 0.97%~1.07%) or concomitant therapy (RR=1.01, 95% CI: 0.95%~1.07%). Conclusion       Bismuth-based quadruple therapy for 10 or 14 d has a comparable efficacy in eradicating H.pylori with sequential therapy and concomitant therapy. Triple therapy and bismuth quadruple therapy for 7 d are not recommended as the primary options for treatment of H.pylori infection.

参考文献/References:

[1]Wang B, Lv Z F, Wang Y H, et al. Standard triple therapy for Helicobacter pylori infection in China: a metaanalysis[J]. World J Gastroenterol, 2014, 20(40): 14973-14985. DOI: 10.3748/wjg.v20.i40.14973.
[2]Xie C, Lu N H. Review: clinical management of Helicobacter pylori infection in China[J]. Helicobacter, 2015, 20(1): 1-10. DOI: 10.1111/hel.12178.
[3]Song Z Q, Zhou L Y. Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and metaanalysis[J]. World J Gastroenterol, 2016, 22(19): 4766-4775. DOI: 10.3748/wjg.v22.i19.4766.
[4]Yeo Y H, Shiu S I, Ho H J, et al. FirstlineHelicobacter pylorieradication therapies in countries with high and low clarithromycin resistance: a systematic review and network metaanalysis[J]. Gut, 2016: gutjnl2016311868. DOI: 10.1136/gutjnl2016311868.
[5]Dore M P, Lu H, Graham D Y. Role of bismuth in improving Helicobacter pylori eradication with triple therapy[J]. Gut, 2016, 65(5): 870-878. DOI: 10.1136/gutjnl2015311019.
[6]Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infectionthe Maastricht V/Florence Consensus Report[J]. Gut, 2017, 66(1): 6-30. DOI: 10.1136/gutjnl2016312288.
[7]Liu W Z, Xie Y, Chen H, et al. The 4th National Consensus on Helicobacter pylori Infection Treatment[J].Chinese Journal of Internal Medicine,2012,51(10): 618-625. DOI: 10.3969/j.issn.10087125.2012.10.010.
[8]张芝华, 张志广, 李熳, 等. 4种含铋剂四联方案根除幽门螺杆菌的临床观察[J]. 天津医科大学学报, 2016, 22(1): 41-43.
Zhang Z H, Zhang Z G, Li M, et al. Clinical observation of four bismuthbased quadruple therapies for eradication of helicobacter pylori[J]. Journal of Tianjin Medical University, 2016, 22(1): 41-43.
[9]王波玲, 高峰. 标准三联与四联方案根除幽门螺杆菌感染成本效果分析[J]. 中国全科医学, 2016, 19(11): 1237-1241. DOI: 10.3969/j.issn.10079572.2016.11.001.
Wang B L, Gao F. Cost  EFfectiveness Analysis of the Eradication of Helicobacter Pylori Infection by Standard Triple Therapy and Quadruple Therapy[J]. Chinese General Practice, 2016, 19(11): 1237-1241. DOI: 10.3969/j.issn.10079572.2016.11.001.
[10]Dai L, Cui M, Yi F U, et al. Efficacy of PPIbased Standard Triple Therapy Combined with Teprenone for Treatment of Helicobacter pylori Infection[J]. Chinese Journal of Gastroenterology, 2016, 21(3): 156-160.
[11]李锐强, 胡宝英. 含铋剂的四联疗法与标准三联疗法对幽门螺杆菌相关性消化性溃疡的疗效对比[J]. 临床消化病杂志, 2015, 27(6): 327-328,329. DOI: 10.3870/lcxh.j.issn.1005541X.2015.06.02.
Li R Q, Hu B Y. Comparative study of the effects of bismuthcontaining quadruple and triple chemotherapy for the treatment with peptic ulcer disease[J]. Chinese Journal of Clinical Gastroenterology, 2015, 27(6): 327-328,329. DOI: 10.3870/lcxh.j.issn.1005541X.2015.06.02.
[12]马军霞. 四联疗法与三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效比较[J].  中国基层医药, 2015,  22(22): 3454-3456. DOI: 10.3760/cma.j.issn.10086706.2015.22.030.
 Ma Junxia. Comparison of the effects of quadruple and triple chemotherapy in the treatment of helicobacter pylori positive peptic ulcer[J]. Chinese Journal of Primary Medicine and Pharmacy, 2015, 22(22): 3454-3456. DOI: 10.3760/cma.j.issn.10086706.2015.22.030.
[13]喻德林, 胡希亚. 含铋剂的四联疗法对消化性溃疡的疗效及对NO、IL10、IL17的影响[J]. 现代消化及介入诊疗, 2015, 20(5): 495-497. DOI: 10.3969/j.issn.16722159.2015.05.010.
Yu D L, Hu X Y. The effect of quadruple therapy including Bismuth on peptic ulcer and its influence of NO,IL10,IL17[J].Modern Digestion & Intervention, 2015, 20(5): 495-497. DOI: 10.3969/j.issn.16722159. 2015.05.010
[14]聂军, 袁晓梅, 吴伟民. 含铋剂四联疗法根除消化性溃疡幽门螺杆菌感染的疗效[J]. 世界华人消化杂志, 2015, 23(14): 2346-2350.
Nie J. Efficacy of bismuth containing quadruple therapy in eradication of Helicobacter pylori in patients with peptic ulcer[J]. World Chinese Journal of Digestology, 2015, 23(14): 2346. DOI: 10.11569/wcjd.v23.i14.2346.
[15]唐捷, 龙云, 苏强, 等. 4种方案治疗幽门螺杆菌感染的疗效比较[J]. 中国药业, 2015, 24(17): 119-120.
Tang Jie, Long Yun, Su Qiang, et al. Efficacy comparison of 4 kinds of treatments for helicobacter pylori infection[J].China Pharmaceuticals, 2015, 24(17): 119-120.
[16]徐娴, 张振玉, 孙为豪. 潘妥洛克联合呋喃唑酮治疗幽门螺杆菌的效果[J]. 世界华人消化杂志, 2015,23(5): 866-870.
Xu X, Zhang Z Y, Sun W H,et al. Effects of pantoprazole combined with furazolidone in Helicobacter pylori eradication therapy[J]. World Chinese Journal of Digestology, 2015, 23(5): 866-870.
[17]郭义茹, 杨玉杰, 李晓霞. 益生菌、铋剂分别联合标准三联与标准三联疗法根除幽门螺杆菌的效果比较[J]. 临床消化病杂志, 2015, 27(2): 90-93. DOI: 10.3870/lcxh.j.issn.1005541X.2015.02.09.
Guo Y R, Yang Y J, Li X X. Comparision of the effects of standard triple therapy and triple therapy combined with probiotic or bismuth on the helicobacter py lori eradication[J]. Chinese Journal of Clinical Gastroenterology, 2015, 27(2): 90-93. DOI: 10.3870/lcxh.j.issn.1005541X.2015.02.09.
[18]王丽昆, 杨娟, 李仲铭, 等. 三联、四联疗法及Boulardii酵母菌在幽门螺杆菌根除治疗中的疗效评估[J]. 昆明医科大学学报, 2015, 36(2): 102-105,114. DOI: 10.3969/j.issn.10034706.2015.02.026.
Wang L K,Yang J,Li Z M,et al.Effectiveness of Saccharomyces boulardii with Triple Therapy or Quadruple Therapy in Helicobacter Pylori Eradication[J].Journal of Kunming Medical University, 2015, 36(2): 102-105.DOI: 10.3969/j.issn.10034706.2015.02.026.
[19]韩思静. 果胶铋四联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效[J]. 中国医药导刊, 2014, 16(10): 1324-1325.
Han S J. Efficacy of bismuth pectin quadruple therapy for helicobacter pyloripositive peptic ulcer[J]. Chinese Journal of Medical Guide, 2014, 16(10): 1324-1325.
[20]李丙生, 甘爱华, 许岸高, 等. 莫西沙星、埃索拉唑和呋喃唑酮三联根除幽门螺杆菌的疗效观察[J]. 中国感染与化疗杂志, 2014, 14(4): 273-275. DOI: 10.3969/j.issn.10097708.2014.04.001.
Li B S, Gan A H, Xu A G, et al. Efficacy of moxifloxacin, esomeprazole plus furazolidone triple therapy to eradicate helicobacter pylori[J]. Chinese Journal of Infection and Chemotherapy, 2014, 14(4): 273-275. DOI: 10.3969/j.issn.10097708.2014.04.001.
[21]吴改玲, 蓝宇. 不同抗生素组合的三种标准三联根除幽门螺杆菌的疗效比较[J]. 中国医药导刊, 2014, 16(3): 463-465.
Wu G L, Lan Y. Comparison of Three Different Standard Antibioticsbased Triple Therapies for Helicobacter Pylori Eradication[J]. Chinese Journal of Medicinal Guide, 2014, 16(3): 463-465.
[22]张健, 李洪运. 四联疗法根治幽门螺旋杆菌感染疗效分析[J]. 中国病原生物学杂志, 2014, 9(8): 747-749. DOI: 10.13350/J.cjpb.140820.
Zhang J, Li H Y. Analysis of the therapeutic effectiveness of a quadruple drug therapy to eradicate Helicobacter pylori[J]. Journal of Pathogen Biology, 2014, 9(8): 747-749. DOI: 10.13350/j.cjpb.140820.
[23]曾丽妮, 练海燕, 潘美云. 培菲康联合三联疗法与含铋剂四联疗法在治疗幽门螺旋杆菌阳性消化性溃疡的疗效比较[J]. 世界华人消化杂志, 2014, 22(21): 3174-3177. DOI: 10.11569/wcjd.v22.i21.3174.
Zeng L N, Lian H Y, Pan M Y. Efficacy and safety of Bifico combined with triple therapy vs bismuth containing quadruple therapy in treatment of Helicobacter pylori positive peptic ulcer[J]. World Chinese Journal of Digestology, 2014, 22(21): 3174-3177. DOI: 10.11569/wcjd.v22.i21.3174.
[24]Xie Y, Zhu Y, Zhou H, et al. Furazolidonebased triple and quadruple eradication therapy for Helicobacter pylori infection[J]. World J Gastroenterol, 2014, 20(32): 11415-11421. DOI: 10.3748/wjg.v20.i32.11415.
[25]金浩淼. 新四联方案治疗幽门螺杆菌阳性消化性溃疡50例的临床对照研究[J]. 中国药业, 2013, 22(10): 23-24. DOI: 10.3969/ j.issn.10064931.2013.10.013.
Jing H M. The observation of the clinical effect for new quadruple therapy in the treatment of 50 cases helicobacter pyloripositive  peptic ulcer[J]. China Pharmaceuticals,2013, 22(10): 23-24.DOI: 10.3969/j.issn.10064931.2013.10.013.
[26]严剑峰. 新四联与标准三联疗法不同疗程根除幽门螺杆菌的临床观察[J]. 中国药业, 2013, 22(7): 54-55. DOI: 10.3969/j.issn.1006 4931.2013.07.033.
Yan J F. The observation of the clinical effect for new quadruple and triple therapy with different courses on eradication of Helicobacter pylori[J].China Pharmaceuticals, 2013, 22(7): 54-55. DOI: 10.3969/j.issn.10064931.2013.07.033.
[27]Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14day levofloxacin triple and triple plus bismuth quadruple therapy[J]. Helicobacter, 2013, 18(5): 373-377. DOI: 10.1111/hel.12052.
[28]程桂莲, 王少峰, 徐丽明, 等. 四联疗法及嗜酸乳杆菌在幽门螺杆菌根除治疗中的疗效评估[J]. 胃肠病学和肝病学杂志, 2013, 22(5): 434-437. DOI: 10.3969/j.issn.10065709.2013.05.013.
Cheng G L, Wang S F, Xu L M, et al. Efficacy of quadruple therapy and lactobacillus acidophilus for helicobacter pylori eradication[J]. Chinese Journal of Gastroenterology and Hepatology, 2013, 22(5): 434-437. DOI: 10.3969/j.issn.10065709.2013.05.013.
[29]谢静, 刘斌. 含铋剂四联疗法根除2型糖尿病患者幽门螺杆菌感染的临床研究[J]. 中南药学, 2012, 10(12): 934-936. DOI: 10.3969/j.issn.1672.2981.2012.12.016.
Xie J, Liu B. Eradication of helicobacter pylori in type 2 diabetes mellitus patients with bismuthbased quadruple therapy[J]. Central South Pharmacy, 2012, 10(12): 934-936. DOI: 10.3969/j.issn.1672.2981.2012.12.016.
[30]赵春明, 周建红, 陆敏学, 等. 含呋喃唑酮、阿莫西林/克拉维酸钾的四联法治疗幽门螺杆菌临床观察[J]. 中国综合临床, 2012, 28(12): 1300-1302. DOI: 10.3760/cma.j.issn.10086315.2012.12.021.
Zhao C M, Zhou J H, Lu M X, et al. Clinical study of furazolidone and amoxicillinpotassium clavulanatebased quadruple regimen on eradication of Helicobacter pylori[J]. Clinical Medicine of China, 2012, 28(12): 1300-1302. DOI: 10.3760/cma.j.issn.10086315.2012. 12.021.
[31]彭美玲, 熊甲英. 四联疗法治疗消化性溃疡效果及影响因素分析[J]. 实用预防医学, 2012, 19(11): 1702-1703. DOI: 10.3969/j.issn.1006 3110.2012.11.038.
Peng M L,Xiong J Y.The study of therapeutic effect and influential factors in quadruple regimen on peptic ulcer patients[J].Practical Prevent ive Medicine, 2012, 19(11): 1702-1703.DOI: 10.3969/j.issn. 10063110.2012.11.038.
[32]赵蕊, 霍丽娟. 不同疗程三联及四联疗法根除幽门螺杆菌疗效观察[J]. 中国实用内科杂志, 2012, 32(10): 796-799.
Zhao R,Hu L J.Efficacy of different terms and different drugs therpy for Helicobacter pylori eradication: a randmoized controlled trial[J]. Chinese Journal of Practical Internal Medicine.2012, 32(10): 796-799.
[33]杨秀英, 张帮杰. 含呋喃唑酮的四联疗法治疗幽门螺杆菌感染的疗效观察[J]. 山东医药, 2012, 52(31): 51-52. DOI: 10.3969/j.issn.1002 266X.2012.31.020.
Yang X Y,Zhang B J.Effect of furazolidone quadruple regimen in the treatment Helicobacter pylori infection[J]. Shandong Medical Journal,2012, 52(31): 51-52.DOI: 10.3969/j.issn.1002266X.2012.31. 020.
[34]章金艳,刘明,栗华,等. 含铋剂四联疗法作为一线方案根除幽门螺杆菌的临床研究[J]. 海南医学, 2012, 23(12): 1214. DOI: 10. 3969/j.issn.1002266X.2012.31.020.
Zhang J Y,Liu M,Li H, et al.Clinical study of bismuthbased quadruple therapy as firstline therapy for the eradication of Helicobacter[J]. HAINAN MEDICAL JOURNAL. 2012, 23(12): 12-14. DOI: 10.3969/j.issn.1002266X.2012.31.020.
[35]徐小青,孙钦娟,廖静贤,等. 含铋剂和克拉霉素的四联根除方案在幽门螺杆菌一线治疗中的作用[J]. 胃肠病学, 2012, 17(1): 5-9. DOI: 10.3969/j.issn.10087125.2012.01.002.
Xu X Q, Sun Q J, Liao J X, et al. Evaluation of bismuthclarithromycincontaining quadruple therapy for initial Helicobacter pylori eradication[J]. Chinese Journal of Gastroenterology, 2012, 17(1): 5-9. DOI: 10.3969/j.issn.10087125.2012.01.002.
[36]陈婉珺, 陈婉, 郑青, 等. 评估以泮托拉唑为基础的三联和四联疗法根除幽门螺杆菌的疗效[J]. 中华消化杂志, 2011, 31(1): 40-44. DOI: 10.3760/cma.j.issn.02541432.2011.01.010.
Chen W J, Chen W, Zheng Q, et al. The evaluation of the efficacy of pantoprazolebased triple and quadruple therapy in helicobacter pylori eradication[J]. Chinese Journal of Digestion , 2011, 31(1): 40-44. DOI: 10.3760/cma.j.issn.02541432.2011.01.010.
[37]丛春莉, 苏秉忠. 左氧氟沙星和呋喃唑酮根除幽门螺杆菌感染的疗效观察[J]. 内蒙古医学院学报, 2009, 31(2): 88-91. DOI: 10.3969/ j.issn.10042113.2009.02.002.
Cong C L, Su B Z. The clinical observation for eradication of helicobacter pylori infection with furazolidone and levofloxacin[J]. Acta Academiae Medicinae Neimongol, 2009, 31(2): 88-91. DOI: 10. 3969/j.issn.10042113.2009.02.002.
[38]Gao X Z, Qiao X L, Song WC, et al. Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication[J]. World J Gastroenterol, 2010, 16(34): 4357-4362. DOI: 10.3748/wjg. v16.i34.4357.
[39]Zheng Q, Chen W J, Lu H, et al. Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance[J]. J Dig Dis, 2010, 11(5): 313-318. DOI: 10.1111/ j.17512980.2010.00457.x.
[40]郑青, 戴军, 李晓波, 等. 以泮托拉唑为基础的三联和四联疗法根除幽门螺杆菌疗效比较——一项单中心、随机、开放、平行对照研究[J]. 胃肠病学, 2009, 14(1): 8-11. DOI: 10.3969/j.issn.1008 7125.2009.01.004.
Zheng Q, Dai J, Li X B, et al. Comparison of the efficacy of pantoprazolebased triple therapy versus quadruple therapy in the treatment of helicobacter pylori infection: a singlecenter, randomized, open and parallelcontrolled study[J]. Chinese Journal of Gastroenterology , 2009, 14(1): 8-11. DOI: 10.3969/j.issn.1008 7125.2009.01.004.
[41]方建武, 曾昭武, 张曙林. 四联疗法治疗HP相关性慢性胃炎疗效研究[J]. 中国现代医学杂志, 2006, 16(22): 3441-3443. DOI: 10.3969/ j.issn.10058982.2006.22.024.
Fang J W, Zeng Z W, Zhang S L. Clinic study of four medicines combination for patients with hp related chronic gastritis[J]. China Journal of Modern Medicine , 2006, 16(22): 3441-3443. DOI: 10.3969/ j.issn.10058982.2006.22.024.
[42]邹夏慧, 刘敦菊, 万德惠, 等. 改良序贯疗法与不同四联疗法根除幽门螺杆菌的疗效分析[J]. 重庆医学, 2016, 45(17): 2372-2374. DOI: 10.3969/j.issn.16718348.2016.17.023.
Zou X H, Liu D J, Wan D H, et al. Efficacy analysis of modified sequential therapy versus different quadruple therapy for eradicating the helicobacter pylori[J]. Chongqing Medicine, 2016, 45(17): 2372-2374. DOI: 10.3969/j.issn.16718348.2016.17.023.
[43]卫金歧, 丛云燕, 黄雪平,等. 艾普拉唑十天标准四联和序贯方案治疗幽门螺杆菌感染慢性胃炎200例的疗效观察[J]. 中华消化杂志, 2014(10): 689-692. DOI: 10.3760/cma.j.issn.02541432.2014.10.008.
Wei J Q,Cong Y Y,Huang X P, et al.Clinical observation on ilaprazole containing tenday standard quadruple therapy and sequential therapy in the treatment of two hundred cases of chronic gastritis with Helicobacter pylori infection[J]. Chin J Dig,2014, 34(10): 689-692. DOI: 10.3760/cma.j.issn.02541432.2014.10.008.
[44]张志宏. 不同治疗方案在幽门螺杆菌感染根除治疗中的疗效观察[J]. 临床消化病杂志, 2014, 26(3): 170-172. DOI: 10.3870/lcxh.j.issn. 1005541X.2014.03.16.
Zhang Z H. Analysis of different protocols in the treatment of Helicobacter pylori[J]. Chin J Clin Gastroenterol, 2014, 26(3): 170-172. DOI: 10.3870/lcxh.j.issn.1005541X.2014.03.16.
[45]李月月,左秀丽,季锐,等. 10天伴同、序贯及含铋剂四联方案根除幽门螺杆菌效果的随机对照研究[J]. 山东大学学报: 医学版, 2014, 52(7): 45-49. DOI: 10.6040/j.issn.16717554.0.2013.750.
Li Y Y, Zuo X L, Ji R, et al.A randomized clinical trial of tenday concomitant, sequential and bismuthbased quadruple therapies for Helicobacter pylori[J].Journal of Shangdong University( Health Sciences), 2014, 52(7): 45-49. DOI: 10.6040/j.issn.16717554.0.2013.750.
[46]孙丽玲. 序贯疗法、四联疗法及标准三联疗法根除幽门螺杆菌的疗效对比分析[J]. 实用临床医药杂志, 2012, 16(21): 105-107.
Sun L L. Comparative analysis of efficacy of sequential therapy, quadruple therapy and standard triple therapy for the eradication of helicobacter pylori[J]. Journal of Clinical Medicine in Practice, 2012, 16(21): 105-107.
[47]张杰, 杨静, 汪海涛, 等. 序贯疗法根除幽门螺杆菌的疗效观察[J]. 天津医药, 2012, 40(1): 79-80. DOI: 10.3969/j.issn.02539896.2012. 01.030.
Zhang J, Yang J, Wang H T, et al.Sequential therapy with esomeprazole in the efficacy of antiHelicobacter pylori[J].Tianjin Medical Journal, 2012, 40(1): 79-80. DOI: 10.3969/j.issn.02539896.2012.01.030.
[48]邹国辉, 刘锋, 左新年, 等. 十天序贯疗法及十天四联疗法与传统三联疗法根除幽门螺杆菌的疗效比较[J]. 中国医师进修杂志, 2011, 34(22): 53-55. DOI: 10.3760/cma.j.issn.16734904.2011.22.021.
Zou G H, Liu F, Zuo X N, et al.The Clinical Curative Effect comparision Of 10day Sequential Therapy、10day quadruple therapy and traditional triple therapy in Eradicating Helicobacter Pylori[J]. Chin J Postgrad Med, 2011, 34(22): 53-55.DOI: 10.3760/cma.j.issn.16734904. 2011.22.021.
[49]Liao X M, Nong G H, Chen M Z, et al. Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection[J]. World J Gastroenterol, 2015, 21(20): 6310-6316. DOI: 10. 3748/wjg.v21.i20.6310.
[50]杨雷, 郝玮玮, 李娅, 等. 不同疗程伴同疗法与含铋剂四联疗法根除幽门螺杆菌的疗效[J]. 世界华人消化杂志, 2015, 23(28): 4589-4594.DOI: 10.11569/wcjd.v23.i28.4589.
Yang L,Hao W W ,Li Y, et al.Efficacy of different courts of concomitant therapy and bism uth containing quadruple therapy for eradication of Helicobacter pylori.Shijie Huaren Xiaohua Zazhi ,2015,23(28): 4589-4594.DOI: 10.11569/wcjd.v23.i28.4589.
[51]陈晓琴, 王岚, 郑洲云, 等. 两种不同药物组成方案根除幽门螺杆菌的疗效及费用评估[J]. 贵阳医学院学报, 2011, 36(6): 630-631. DOI: 10.3969/j.issn.10002707.2011.06.029.
Chen X Q,Wang L,Zheng Z Y, et al.Efficacy and cost estimation of therapy combined two kinds of different drugs for eradication of Helicobacter pylori[J]. Journal of Guiyang Medical College, 2011, 36(6): 630-631.DOI: 10.3969/j.issn.10002707.2011.06.029.
[52]Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis[J]. Gut, 2015, 64(9): 1353-1367. DOI: 10.1136/gutjnl2015309252.
[53]Chen Q, Lu H. Kyoto global consensus report on Helicobacter pylori gastritis and its impact on Chinese clinical practice[J]. J Dig Dis, 2016, 17(6): 353-356. DOI: 10.1111/17512980.12358.
[54]黄继平, 黄艳娟, 袁小刚, 等. 深圳龙岗地区幽门螺杆菌耐药状况分析及耐药对治疗的影响[J]. 实用医学杂志, 2015, 31(14): 2382-2384. DOI: 10.3969/j.issn.10065725.2015.14.045.
Huang J P, Huang Y J, Yuan X G, et al. Prevalence of Helicobacter pylori Resistance to Antibiotics and its Influence on the Treatment Outcome in Longgang district,Shenzhen[J]. The Journal of Practical Medicine, 2015, 31(14): 2382-2384. DOI: 10.3969/j.issn.10065725.2015.14.045.
[55]张维, 陆红. 含铋剂的根除幽门螺杆菌方案在我国应用的经验与建议[J]. 中华消化杂志, 2014, 34(9): 646-648. DOI: 10.3760/cma.j.issn. 02541432.2014.09.022.
Zhang W,Huang Y J,Yuan X G, et al. The experience and suggestion of Helicobacter pylori eradication therapy contained bismuth in our country[J]. Chin J Dig, 2014, 34(9): 646-648. DOI: 10.3760/cma.j. issn.02541432.2014.09.022.
[56]徐美华, 张桂英, 李常娟, 等. 含铋剂四联一线治疗方案根除幽门螺杆菌疗效观察[J]. 浙江大学学报(医学版), 2011, 40(3): 327-331. DOI: 10.3785/j.issn.10089292.2011.03.017.
Xu M H, Zhang G Y, Li C J. Efficacy of bismuthbased quadruple therapy as firstline treatment for Helicobacter pylori infection[J]. Journal of Zhejiang University Medical sciences, 2011, 40(3): 327-331. DOI: 10.3785/j.issn.10089292.2011.03.017.
[57]Sun Q, Liang X, Zheng Q, et al. High efficacy of 14day triple therapybased, bismuthcontaining quadruple therapy for initial helicobacter pylori eradication[J]. Helicobacter, 2010, 15(3): 233. DOI: 10.1111/j.15235378.2010.00758.x.
[58]LienChieh, TzuHerng, KuangWei, et al. Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A metaanalysis of randomized controlled trials[J]. World Journal of Gastroenterology, 2016, 22(23): 5445-5453. DOI: 10.3748/wjg.v22.i23. 5445.
[59]张少君, 董小林. 序贯疗法与伴同疗法根除幽门螺杆菌疗效的Meta分析[J]. 胃肠病学和肝病学杂志, 2016, 25(7): 773-778. DOI: 10.3969/j.issn.10065709.2016.07.015.
ZHANG Shaojun, DONG Xiaolin. Sequential therapy and concomitant therapy for helicobacter pylori eradication: a metaanalysis[J]. Chinese Journal of Gastroenterology and Hepatology, 2016, 25(7): 773-778. DOI: 10.3969/j.issn.10065709.2016.07.015.

更新日期/Last Update: 2017-05-22